Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Antimicrobial Susceptibility Testing Market – Insights
Increasing number of pathogenic bacteria are acquiring antibiotic resistance and new forms of resistance are continuously emerging, which enable clinicians to perform antimicrobial susceptibility testing (AST) on priority. A rapid multiplexed AST platform provides minimum inhibitory concentrations (MICs) within hours at reasonable cost, which enables rapid determination of effective targeted therapy, resulting in short hospital stays, few laboratory tests, and decreasing morbidity and mortality along with associated healthcare expenses.
The global antimicrobial susceptibility testing market size was valued at US$ 2.65 billion in 2017 and is expected to witness a CAGR of 6.2% over the forecast period (2018 – 2026).
Global Antimicrobial Susceptibility Testing Market Share (%) Analysis, By Product Type, 2017
Source: Coherent Market Insights Analysis (2019)
Emergence of Multidrug Resistance Worldwide Is Expected To Drive the Antimicrobial Susceptibility Testing Market Revenue
Resistance among various microbial species to different antimicrobial drugs have emerged as a major cause of public health threat. According to World Health Organization (WHO), these resistant microorganisms such as bacteria, fungi, viruses, and parasites are able to combat attack by antimicrobial drugs, which leads to ineffective treatment resulting in persistence and spreading of infections.
Increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and others among the global population is expected to result in increasing adoption of antimicrobial susceptibility testing to reduce the resistance exposure during the forecast period. For instance, according to the WHO, in 2016, an estimated 490,000 people worldwide developed MDR-TB. The countries with the largest numbers of MDR/RR-TB cases were China, India and the Russian Federation.
Moreover, development of genotypic-based methods offering rapid and accurate detection or confirmation of antimicrobial resistance is expected to drive the market growth. For instance, the Accelerate ID/AST System or ID/AST System (Accelerate) aims to reduce the turnaround time by using genetic methods. The device can identify infectious pathogens in a matter of hours instead of days, reducing diagnostic time by 30 to 50 hours.
Antimicrobial Susceptibility Testing Market Restraints
Stringent government regulations is the major restraining factor for the antimicrobial susceptibility testing market growth. Regulatory procedures creates barrier to AST development, as clinical validation and trials are lengthy and often too costly for small-sized or medium-sized enterprises or organizations.
For instance, in the U.S., a manufacturer who intends to market a device of generic type must conform to the general controls of Section 513(a)(1)(B) of the Federal Food, Drug and Cosmetic Act, address the risks to health associated with the AST system, and obtain a substantial equivalence assessment from the FDA.
Antimicrobial Susceptibility Testing Market - Regional Insights
On the basis of region, the global antimicrobial susceptibility testing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the most lucrative region in the antimicrobial susceptibility testing market in 2017 due to the emergence of a multidrug resistant strain of Salmonella in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), September 2018, around two million people are infected with antibiotic-resistant bacteria in the U.S. annually and around 23,000 people die as a result. Moreover, government agencies in the U.S. have taken steps to prevent and control antibiotic resistance, which is expected to increase the adoption of antimicrobial susceptibility testing in the country.
Asia Pacific antimicrobial susceptibility testing market revenue is expected to foresee significant growth over the forecast period due to high prevalence of microbial infections and increasing consumption of antibiotics, eventually developing resistance among the population. According to a WHO report, in 2014, multidrug-resistant tuberculosis rates were high in India and treatment for the disease is generally limited.
Global Antimicrobial Susceptibility Testing Market Value (US$ Mn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2019)
Key players operating in the global antimicrobial susceptibility testing market include bioMérieux S.A., HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, Resistell AG, Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Merck KGaA, and Bio-Rad Laboratories, Inc.